$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Treating opiate dependence 원문보기

IPC분류정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판)
  • A61K-031/44
출원번호 US-0276400 (1988-11-25)
우선권정보 GB-0028294 (1987-12-03)
발명자 / 주소
  • Lewis John W. (North Humberside GBX)
출원인 / 주소
  • Reckitt & Colman Products Limited (London GB2 03)
인용정보 피인용 횟수 : 106  인용 특허 : 1

초록

A pharmaceutical composition in sublingual unit dosage form for maintenance treatment of opiate addicts comprising from 2 to 8 mg buprenorphine and an amount of naltrexone sufficient to substantially attenuate the euphorigenic effect of the buprenorphine when injected and to provide greater opiate b

대표청구항

A method of treating opiate dependent subjects in which addicts are treated by sublingual administration with a daily dose of 2 to 8 mg buprenorphine for 1 to 4 weeks followed by, as maintenance treatment, the daily simultaneous administration sublingually of 2 to 8 mg buprenorphine and an amount of

이 특허에 인용된 특허 (1)

  1. Lewis John W. (North Ferriby GB2) Lloyd-Jones John G. (Cottingham GB2), Analgesic compositions.

이 특허를 인용한 특허 (106)

  1. Matthews, Frank; Boehm, Garth; Tang, Lijuan; Liang, Alfred, Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist.
  2. Matthews, Frank; Boehm, Garth; Tang, Lijuan; Liang, Alfred, Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist.
  3. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  4. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  5. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  6. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  7. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  8. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  9. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  10. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  11. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  12. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  13. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  14. Mehta, Atul M., Abuse-resistant oral dosage forms and method of use thereof.
  15. Mehta, Atul M., Abuse-resistant oral dosage forms and method of use thereof.
  16. Mehta, Atul M., Abuse-resistant oral dosage forms and method of use thereof.
  17. Fischer, Andreas, Abuse-resistant pharmaceutical composition for the treatment of opioid dependence.
  18. Fischer, Andreas, Abuse-resistant pharmaceutical composition for the treatment of opioid dependence.
  19. Fischer, Andreas, Abuse-resistant pharmaceutical composition for the treatment of opioid dependence.
  20. Fischer, Andreas, Abuse-resistant pharmaceutical composition for the treatment of opioid dependence.
  21. Caruso Frank S., Analgesic composition and method for treating pain.
  22. Oksche, Alexander; Heath, William; Holden, Timothy; Prater, Derek A.; Sackler, Richard S.; Walden, Malcolm, Buprenorphine-wafer for drug substitution therapy.
  23. Oksche, Alexander; Heath, William; Holden, Timothy; Prater, Derek A.; Sackler, Richard S.; Walden, Malcolm, Buprenorphine-wafer for drug substitution therapy.
  24. Oksche, Alexander; Heath, William; Holden, Timothy; Prater, Derek A.; Sackler, Richard S.; Walden, Malcolm, Buprenorphine-wafer for drug substitution therapy.
  25. Oksche, Alexander; Heath, William; Holden, Timothy; Prater, Derek A.; Sackler, Richard S.; Walden, Malcolm, Buprenorphine-wafer for drug substitution therapy.
  26. Von Coburg, Yvonne; Reimer, Karen; Oksche, Alexander; Holzer, Peter, Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation.
  27. Oshlack, Benjamin; Wright, Curtis, Controlled-release compositions containing opioid agonist and antagonist.
  28. Nuwayser,Elie S., High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence.
  29. Danagher, Helen Kathleen; Hayes, Geoffrey Gerard; Heun, Gerhard Josef; Mohammad, Hassan; Walden, Malcolm; Whitehouse, Jonathon Oliver, Immediate release pharmaceutical compositions comprising oxycodone and naloxone.
  30. Danagher, Helen Kathleen; Hayes, Geoffrey Gerard; Heun, Gerhard Josef; Mohammad, Hassan; Walden, Malcolm; Whitehouse, Jonathon Oliver, Immediate release pharmaceutical compositions comprising oxycodone and naloxone.
  31. Patel, Rajesh A.; Bucalo, Louis R.; Costantini, Lauren; Kleppner, Sofie, Implantable polymeric device for sustained release of dopamine agonist.
  32. Patel, Rajesh A.; Bucalo, Louis R.; Costantini, Lauren; Kleppner, Sofie, Implantable polymeric device for sustained release of dopamine agonist.
  33. Thomas R. Tice ; Jay K. Staas ; Teresa M. Ferrell ; Peter Markland, Injectable opioid partial agonist or opioid antagonist microparticle compositions and their use in reducing consumption of abused substances.
  34. Brögmann, Bianca; Muhlau, Silke; Spitzley, Christof, Matrix for sustained, invariant and independent release of active compounds.
  35. Brögmann, Bianca; Mühlah, Silke; Spitzley, Christof, Matrix for sustained, invariant and independent release of active compounds.
  36. Brögmann, Bianca; Mühlau, Silke; Spitzley, Christof, Matrix for sustained, invariant and independent release of active compounds.
  37. Leyendecker, Petra; Hopp, Michael; Drews, Axel, Method and device for the assessment of bowel function.
  38. Sinclair John D. (Nokkalanniemi 7 SF-02230 Espoo FIX), Method for terminating methadone maintenance through extinction of the opiate-taking responses.
  39. Palermo Philip J. ; Colucci Robert D. ; Kaiko Robert F., Method of preventing abuse of opioid dosage forms.
  40. Palermo, Philip J.; Kaiko, Robert F.; Colucci, Robert D., Method of preventing abuse of opioid dosage forms.
  41. Crain,Stanley M.; Shen,Ke fei, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists.
  42. Eswara Amruta R. ; Muni Neal ; Schneider F. Howard ; Mione Peter J., Methods and articles of manufacture for nicotine cessation and monitoring nicotine use.
  43. Lee Eun Soo ; Watanabe Tyler ; Gale Robert M. ; Burkoth Terry L., Monoglyceride/lactate ester permeation enhancer for oxybutnin.
  44. Lee Eun Soo ; Watanabe Tyler ; Gale Robert M. ; Burkoth Terry L., Monoglyceride/lactate ester permeation enhancer for oxybutynin.
  45. Nuwayser,Elie S., Multi-layered microcapsules and method of preparing same.
  46. Jansen, Rolf R.; Coronado, Dina J., Multilayer drug delivery system with barrier against reservoir material flow.
  47. Pettersson, Anders, Non-abusable pharmaceutical composition comprising opioids.
  48. Breder, Christopher; Wright, Curtis; Oshlack, Benjamin, Opiod agonist formulations with releasable and sequestered antagonist.
  49. Kaiko,Robert F.; Colucci,Robert D., Opioid agonist / antagonist combinations.
  50. Breder, Christopher; Wright, Curtis; Oshlack, Benjamin, Opioid agonist formulations with releasable and sequestered antagonist.
  51. Breder, Christopher; Wright, Curtis; Oshlack, Benjamin, Opioid agonist formulations with releasable and sequestered antagonist.
  52. Breder, Christopher; Wright, Curtis; Oshlack, Benjamin, Opioid agonist formulations with releasable and sequestered antagonist.
  53. Kaiko Robert F. ; Colucci Robert D., Opioid agonist/antagonist combinations.
  54. Kaiko, Robert F.; Colucci, Robert D., Opioid agonist/antagonist combinations.
  55. Kaiko, Robert F.; Colucci, Robert D., Opioid agonist/antagonist combinations.
  56. Kaiko, Robert F.; Colucci, Robert D., Opioid agonist/antagonist combinations.
  57. Kaiko, Robert F.; Colucci, Robert D., Opioid agonist/antagonist combinations.
  58. Kaiko, Robert F.; Colucci, Robert D., Opioid agonist/antagonist combinations.
  59. Kaiko, Robert F.; Colucci, Robert D., Opioid agonist/antagonist combinations.
  60. Kaiko,Robert F.; Colucci,Robert D., Opioid agonist/antagonist combinations.
  61. Robert F. Kaiko ; Robert D. Colucci, Opioid agonist/antagonist combinations.
  62. Kaiko, Robert F.; Colucci, Robert D., Opioid agonist/opioid antagonist/acetaminophen combinations.
  63. Kaiko, Robert F.; Colucci, Robert D., Opioid agonist/opioid antagonist/acetaminophen combinations.
  64. Kaiko, Robert F.; Colucci, Robert D., Opioid agonist/opioid antagonist/acetaminophen combinations.
  65. Robert F. Kaiko ; Robert D. Colucci, Opioid agonist/opioid antagonist/acetaminophen combinations.
  66. Fleischer, Wolfgang; Reimer, Karen; Leyendecker, Petra, Opioids for the treatment of the chronic obstructive pulmonary disease (COPD).
  67. Wright, IV, Curtis; Carpanzano, Anthony E., Oral dosage form comprising a therapeutic agent and an adverse-effect agent.
  68. Wright, IV,Curtis; Carpanzano,Anthony E., Oral dosage form comprising a therapeutic agent and an adverse-effect agent.
  69. Kao, Haui-Hung; Baichwal, Anand R.; McCall, Troy; Lee, David, Oxymorphone controlled release formulations.
  70. Kao, Huai-Hung; Baichwal, Anand R.; McCall, Troy; Lee, David, Oxymorphone controlled release formulations.
  71. Liang, Alfred; Matthews, Frank; Boehm, Garth; Tang, Lijuan; Johnson, Frank; Stauffer, Joseph, Pharmaceutical composition.
  72. Matthews, Frank; Boehm, Garth; Tang, Lijuan; Liang, Alfred, Pharmaceutical composition.
  73. Matthews, Frank; Boehm, Garth; Tang, Lijuan; Liang, Alfred, Pharmaceutical compositions.
  74. Matthews, Frank; Boehm, Garth; Tang, Lijuan; Liang, Alfred, Pharmaceutical compositions for the deterrence and/or prevention of abuse.
  75. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  76. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  77. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  78. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  79. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  80. Brögmann, Bianca; Mühlau, Silke; Spitzley, Christof, Pharmaceutical preparation containing oxycodone and naloxone.
  81. Brögmann, Bianca; Mühlau, Silke; Spitzley, Christof, Pharmaceutical preparation containing oxycodone and naloxone.
  82. Oshlack, Benjamin; Van Buskirk, Glenn; Chasin, Mark; Huang, Hua-Pin; Vashi, Vijay, Pharmaceutical product comprising a sequestered agent.
  83. Oshlack, Benjamin; Van Buskirk, Glenn; Chasin, Mark; Huang, Hua-Pin; Vashi, Vijay, Pharmaceutical products.
  84. Breder, Christopher; Oshlack, Benjamin; Wright, Curtis, Sequestered antagonist formulations.
  85. Breder, Christopher; Oshlack, Benjamin; Wright, Curtis, Sequestered antagonist formulations.
  86. Boehm, Garth, Sequestering subunit and related compositions and methods.
  87. Boehm, Garth, Sequestering subunit and related compositions and methods.
  88. Myers, Garry L.; Hilbert, Samuel D.; Boone, Bill J.; Bogue, Beuford Arlie; Sanghvi, Pradeep; Hariharan, Madhusudan, Sublingual and buccal film compositions.
  89. Baichwal,Anand R.; Kao,Huai Hung; McCall,Troy W., Sustained release formulations of oxymorphone.
  90. Stalling Reginald W. (314 Golf Course Rd. Owings Mills MD 21117-4114), Symptom controlled receptor substitution for addiction withdrawl.
  91. Oshlack, Benjamin; Wright, Curtis; Haddox, J. David, Tamper resistant oral opioid agonist formulations.
  92. Oshlack, Benjamin; Wright, Curtis; Haddox, J. David, Tamper-resistant oral opioid agonist formulations.
  93. Oshlack, Benjamin; Wright, Curtis; Haddox, J. David, Tamper-resistant oral opioid agonist formulations.
  94. Oshlack, Benjamin; Wright, Curtis; Haddox, J. David, Tamper-resistant oral opioid agonist formulations.
  95. Oshlack, Benjamin; Wright, Curtis; Haddox, J. David, Tamper-resistant oral opioid agonist formulations.
  96. Oshlack, Benjamin; Wright, Curtis; Haddox, J. David, Tamper-resistant oral opioid agonist formulations.
  97. Oshlack, Benjamin; Wright, Curtis; Haddox, J. David, Tamper-resistant oral opioid agonist formulations.
  98. Oshlack, Benjamin; Wright, Curtis; Haddox, J. David, Tamper-resistant oral opioid agonist formulations.
  99. Oshlack, Benjamin; Wright, Curtis; Haddox, J. David, Tamper-resistant oral opioid agonist formulations.
  100. Oshlack, Benjamin; Wright, Curtis; Haddox, J. David, Tamper-resistant oral opioid agonist formulations.
  101. Oshlack, Benjamin; Wright, Curtis; Haddox, J.David, Tamper-resistant oral opioid agonist formulations.
  102. Oshlack, Benjamin; Wright, Curtis; Haddox, J.David, Tamper-resistant oral opioid agonist formulations.
  103. Oshlack, Benjamin; Wright, Curtis; Haddox, J.David, Tamper-resistant oral opioid agonist formulations.
  104. Gale, Robert M.; Stein, Thomas M.; Audett, Jay; Stepic, Jane; Phipps, Joseph B.; Cormier, Michael J. N., Transdermal analgesic systems with reduced abuse potential.
  105. Gale, Robert M.; Stein, Thomas M.; Audett, Jay; Stepic, Jane; Phipps, Joseph B.; Cormier, Michel J. N., Transdermal analgesic systems with reduced abuse potential.
  106. Stinchcomb, Audra L.; Swaan, Peter W., Transdermal delivery of opioid antagonist prodrugs.
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로